Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials. Issue 6 (27th June 2022)

• Record Type: Journal Article
• Authors: Boczar, Kevin Emery; Shin, Sheojung; Bezzina, Kathryn A; Geejo, Aishwarya; Pearson, Alexander Liam; Shahab, Saba; Fehlmann, Christophe A; Visintini, Sarah; Beanlands, Rob; Wells, George A
• Is Part Of: BMJ open. Volume 12:Issue 6(2022)
• Publication Date: 2022-06-27
• Subjects: Myocardial infarction -- CARDIOLOGY -- Cardiac Epidemiology; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2022-062702
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Inflammation is emerging as an important risk factor for atherosclerotic cardiovascular disease and has been a recent target for many novel therapeutic agents. However, comparative evidence regarding efficacy of these anti-inflammatory treatment options is currently lacking. Methods and analysis: This systematic review will include randomised controlled trials evaluating the effect of anti-inflammatory agents on cardiovascular outcomes in patients with known cardiovascular disease. Studies will be retrieved from Medline, Embase, the Cochrane Central Register of Controlled Trials, as well as clinical trial registry websites, Europe PMC and conference abstract handsearching. No publication date or language restrictions will be imposed. Eligible interventions must have some component of anti-inflammatory agent. These include (but are not limited to): non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, prednisone, methotrexate, canakinumab, pexelizumab, anakinra, succinobucol, losmapimod, inclacumab, atreleuton, LP-PLA2 (darapladib) and sPLA2 (varespladib). The primary outcomes will include major adverse cardiac events (MACE), and each individual component of MACE (myocardial infarction, stroke and cardiovascular death). Key secondary outcomes will include unstable angina, heart failure, all-cause mortality, cardiac arrest and revascularisation. Screening, inclusion, data extraction and quality assessment will be performed independently by two reviewers. Network meta-analysis based on the random effects model will be conducted to compare treatment effects both directly and indirectly. The quality of the evidence will be assessed with appropriate tools including the Grading of Recommendations, Assessment, Development and Evaluation profiler or Confidence in Network Meta-Analysis tool. Ethics and dissemination: Ethics approval is not required for this systematic review. The findings will be disseminated through a peer-reviewed journal. PROSPERO registration number: CRD42022303289.